Addressing the impact of different fetal bovine serum percentages on mesenchymal stem cells biological performance (original) (raw)

Abstract

Human mesenchymal stem cells (MSCs) are presently on the top of hierarchy in the field of stem cell therapy, due to their miraculous therapeutic abilities in diminishing the symptoms of many chronic diseases and initiating regeneration and repair for various damaged tissues and organs. The foremost initial step to reach high success rate in any MSCs based study is the optimization of culture growth media by establishing a suitable fetal bovine serum (FBS) percentage that suits the purpose of MSCs based experiment. Choosing the suitable FBS percentage is a controversial issue and merely depends on the researchers experience and suggested recommendations by the suppliers. Despite the huge improvements in overall MSCs investigating approaches, there are no definite protocols that set up a range of FBS percentages that can be followed. Toward achieving this objective, we evaluate in the present report the effect of using various FBS percentages (5–20%) added to DMEM low glucose media, on the biological behaviour of MSCs. Growing MSCs in high FBS percentages containing culture media (15% and 20% FBS) increase the proliferation and expansion rate of MSCs, although it decreases the immunosuppressive properties. On the other hand, adding low FBS percentage (7% FBS) to MSCs culture media enhanced the immunosuppression characteristics of MSCs, even though the proliferation rate was moderately reduced. 7% FBS is the cut off percentage that can be used without negatively altering major MSCs biological properties in which using 5% FBS will cause a tremendous decrease in the proliferation capacity and immunosuppressive properties. This report may assist other researchers in choosing appropriate FBS percentage when preparing MSCs culture media that serve the purpose of their MSCs based studies.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

The alternative text for this image may have been generated using AI.

Fig. 2

The alternative text for this image may have been generated using AI.

Fig. 3

The alternative text for this image may have been generated using AI.

Similar content being viewed by others

References

  1. Dahl JA et al (2008) Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. Int J Dev Biol 52(8):1033–1042
    Article CAS PubMed Google Scholar
  2. Karantalis V, Hare JM (2015) Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res 116(8):1413–1430
    Article CAS PubMed PubMed Central Google Scholar
  3. Campagnoli C (2001) Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 98(8):2396–2402
    Article CAS PubMed Google Scholar
  4. Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8(9):726–736
    Article CAS PubMed Google Scholar
  5. Abu-El-Rub E et al (2019) Hypoxia-induced 26S proteasome dysfunction increases immunogenicity of mesenchymal stem cells. Cell Death Dis 10(2):90
    Article CAS PubMed PubMed Central Google Scholar
  6. Kharaziha P et al (2009) Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 21(10):1199–1205
    Article CAS PubMed Google Scholar
  7. Bang OY et al (2005) Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 57(6):874–882
    Article PubMed Google Scholar
  8. Le Blanc K et al (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. The Lancet 371(9624):1579–1586
    Article CAS Google Scholar
  9. Adak S, Mukherjee S, Sen D (2017) Mesenchymal stem cell as a potential therapeutic for inflammatory bowel disease—myth or reality? Curr Stem Cell Res Ther 12(8):644–657
    Article CAS PubMed Google Scholar
  10. Calonge M et al (2018) A proof-of-concept clinical trial using mesenchymal stem cells for the treatment of corneal epithelial stem cell deficiency. Transl Res 206:18–40
    Article PubMed Google Scholar
  11. Trounson A, McDonald C (2015) Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17(1):11–22
    Article CAS PubMed Google Scholar
  12. Ullah I, Subbarao RB, Rho GJ (2015) Human mesenchymal stem cells—current trends and future prospective. Biosci Rep 35(2):e00191
    Article CAS PubMed PubMed Central Google Scholar
  13. Barberi T et al (2005) Derivation of multipotent mesenchymal precursors from human embryonic stem cells. PLoS Med 2(6):e161
    Article CAS PubMed PubMed Central Google Scholar
  14. Bieback K et al (2009) Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 27(9):2331–2341
    Article CAS PubMed Google Scholar
  15. Sareen N et al (2018) Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior. Stem Cell Res Ther 9(1):121
    Article CAS PubMed PubMed Central Google Scholar
  16. Jung S et al (2012) Ex vivo expansion of human mesenchymal stem cells in defined serum-free media. Stem Cells Int 2012:123030
    Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

This study was funded by a grant from the deanship of Research at Yarmouk University.

Author information

Author notes

Authors and Affiliations

  1. Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan
    Ramada R. Khasawneh, Ejlal Abu-El Rub & Hayam Nizar Obeidat
  2. Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
    Ahmed Hesham Al Sharie & Abdullah Omar Serhan
  3. Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, Canada
    Ejlal Abu-El Rub

Authors

  1. Ramada R. Khasawneh
  2. Ahmed Hesham Al Sharie
  3. Ejlal Abu-El Rub
  4. Abdullah Omar Serhan
  5. Hayam Nizar Obeidat

Corresponding author

Correspondence toRamada R. Khasawneh.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ramada R. Khasawneh and Ahmed Hesham Al Sharie have contributed equally to this work.

Rights and permissions

About this article

Cite this article

Khasawneh, R.R., Al Sharie, A.H., Abu-El Rub, E. et al. Addressing the impact of different fetal bovine serum percentages on mesenchymal stem cells biological performance.Mol Biol Rep 46, 4437–4441 (2019). https://doi.org/10.1007/s11033-019-04898-1

Download citation

Keywords